These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17509137)

  • 1. Cost-effectiveness analysis of a state funded programme for control of severe asthma.
    Franco R; Santos AC; do Nascimento HF; Souza-Machado C; Ponte E; Souza-Machado A; Loureiro S; Barreto ML; Rodrigues LC; Cruz AA
    BMC Public Health; 2007 May; 7():82. PubMed ID: 17509137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic impact of severe asthma to low-income families.
    Franco R; Nascimento HF; Cruz AA; Santos AC; Souza-Machado C; Ponte EV; Souza-Machado A; Rodrigues LC; Barreto ML
    Allergy; 2009 Mar; 64(3):478-83. PubMed ID: 19210355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled study to evaluate the role of an in-home asthma disease management program provided by respiratory therapists in improving outcomes and reducing the cost of care.
    Shelledy DC; Legrand TS; Gardner DD; Peters JI
    J Asthma; 2009 Mar; 46(2):194-201. PubMed ID: 19253130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource utilization and cost of rheumatic fever.
    Terreri MT; Ferraz MB; Goldenberg J; Len C; Hilário MO
    J Rheumatol; 2001 Jun; 28(6):1394-7. PubMed ID: 11409136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quality assurance of drug therapy for patients with asthma. Health economic analysis].
    Søndergaard B; Thorleifsson S; Herborg H; Frøkjaer B; Hepler CD; Ersbøll BK
    Ugeskr Laeger; 2000 Jan; 162(4):480-6. PubMed ID: 10697444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of inhaled corticosteroid delivery for children with asthma in the emergency department.
    Andrews AL; Teufel RJ; Basco WT; Simpson KN
    J Pediatr; 2012 Nov; 161(5):903-7. PubMed ID: 22717219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of a disease management programme in asthma].
    Petro W; Schulenburg JM; Greiner W; Weithase J; Schülke A; Metzdorf N
    Pneumologie; 2005 Feb; 59(2):101-7. PubMed ID: 15724223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a structured treatment and teaching programme on asthma.
    Trautner C; Richter B; Berger M
    Eur Respir J; 1993 Nov; 6(10):1485-91. PubMed ID: 8112443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities.
    O'Connor RD; Parasuraman B; Roberts C; Leibman C
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):236-43. PubMed ID: 16937758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.
    Sullivan SD; Buxton M; Andersson LF; Lamm CJ; Liljas B; Chen YZ; Pauwels RA; Weiss KB
    J Allergy Clin Immunol; 2003 Dec; 112(6):1229-36. PubMed ID: 14657888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals.
    Kim SH; Kim TW; Kwon JW; Kang HR; Lee YW; Kim TB; Kim SH; Park HW; Park SW; Chang YS; Cho YS; Park JW; Cho YJ; Yoon HJ; Cho SH; Choi BW; Moon HB; Min KU
    J Asthma; 2012 Apr; 49(3):303-9. PubMed ID: 22185405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation.
    Doan T; Grammer LC; Yarnold PR; Greenberger PA; Patterson R
    Ann Allergy Asthma Immunol; 1996 Jun; 76(6):513-8. PubMed ID: 8673685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in clinical, pulmonary function, quality of life and costs in a cohort of asthmatic patients followed for 10 years.
    Serra Batlles J; Plaza V; Comella A
    Arch Bronconeumol; 2011 Oct; 47(10):482-7. PubMed ID: 21852031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.
    Sawicki GS; Vilk Y; Schatz M; Kleinman K; Abrams A; Madden J
    J Asthma; 2010 Jun; 47(5):574-80. PubMed ID: 20560831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of an interventional program on resource use and cost in pediatric asthma.
    Higgins JC; Kiser WR; McClenathan S; Tynan NL
    Am J Manag Care; 1998 Oct; 4(10):1465-9. PubMed ID: 10338738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study.
    Dal Negro RW; Micheletto C; Tosatto R; Dionisi M; Turco P; Donner CF
    Respir Med; 2007 Dec; 101(12):2511-9. PubMed ID: 17822890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a pediatric asthma management program provided by respiratory therapists on patient outcomes and cost.
    Shelledy DC; McCormick SR; LeGrand TS; Cardenas J; Peters JI
    Heart Lung; 2005; 34(6):423-8. PubMed ID: 16324962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The public health implications of asthma.
    Bousquet J; Bousquet PJ; Godard P; Daures JP
    Bull World Health Organ; 2005 Jul; 83(7):548-54. PubMed ID: 16175830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma.
    Oba Y; Salzman GA
    J Allergy Clin Immunol; 2004 Aug; 114(2):265-9. PubMed ID: 15316501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.